From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications

Area of Science:

• Gastroenterology and immunology
• Inflammatory Bowel Disease (IBD) research
• Precision medicine in IBD

Background:

• Anti-tumor necrosis factor (anti-TNF) therapy is a primary treatment for moderate to severe Crohn's disease (CD).
• Approximately 40% of CD patients do not achieve clinical benefit from anti-TNF therapy.
• Limitations in current single-target therapies include safety, efficacy, and achieving long-term remission.

Purpose of the Study:

• To review current therapeutic strategies for managing Crohn's disease.
• To highlight recent advancements in understanding the cellular and molecular drivers of CD.
• To propose new frameworks for advancing CD treatment towards precision therapeutics.

Main Methods:

• Review of current literature on Crohn's disease therapeutics.
• Analysis of cellular and molecular mechanisms in CD tissue lesions.
• Examination of genetic and genomic data guiding treatment strategies.

Main Results:

• Incomplete cellular targeting and delayed treatment initiation contribute to anti-TNF therapy failure.
• Understanding the cellular and molecular circuitry of tissue lesions is crucial for effective treatment.
• Combinatorial strategies targeting specific cellular niches show promise.

Conclusions:

• Current CD treatments have significant limitations in efficacy and long-term remission.
• Advancing CD management requires a deeper understanding of pathogenic niche activation.
• Future strategies should integrate combinatorial therapies, serial tissue sampling, and genetics-guided approaches for precision therapeutics in IBD.